Exelixis | EXEL - Spese Operative





Spese Operative Cambiamento Data
Acadia Pharmaceuticals USD 270.12M 2.55M 2026-06
Agios Pharmaceuticals USD 130.77M 10.77M 2026-03
Akebia Therapeutics USD 63.08M 8.26M 2025-12
Amgen USD 11.69B 6.9B 2026-06
AstraZeneca USD 12.22B 4.04B 2026-06
Bayer EUR 10.04B 168M 2026-06
BioMarin Pharmaceutical USD 6.32B 5.69B 2026-06
Bristol-Myers Squibb USD 22.32B 2.25B 2026-06
Cytokinetics USD 207.8M 7.22M 2026-06
Eisai JPY 209.6B 6.14B 2026-06
Eli Lilly USD 10.52B 496M 2026-06
Exelixis USD 380.28M 20.8M 2026-06
Genmab DKK 748M 77M 2026-06
Glaxosmithkline GBP 5.34B 3.83B 2026-03
Incyte USD 973.64M 4.65B 2026-06
Ionis Pharmaceuticals USD 370.24M 6.24M 2026-06
MacroGenics USD 42.87M 21.68M 2026-06
Merck USD 15.77B 2.4B 2026-06
Moderna USD 960M 817M 2026-06
Nektar Therapeutics USD 49.12M 8.22M 2026-03
Neurocrine Biosciences USD 739.1M 139.2M 2026-06
Novartis USD 10.2B 912M 2026-06
Pfizer USD 85.19B 4.91B 2026-06
Puma Biotechnology USD 49.26M 3.2M 2024-06
Sanofi EUR 8.98B 1.73B 2026-03
Takeda JPY 1.02T 89.68B 2026-06
Ultragenyx Pharmaceutical USD 289M 16M 2026-06
Xencor USD 87.82M 5.44M 2026-06